WS #10070
Biogen acquires RayThera for up to $1B to expand immunology pipeline, lead asset entering Phase 1 in Q3 2026.
Biogen Acquires RayThera
Biogen acquires RayThera for up to $1B to expand immunology pipeline, lead asset entering Phase 1 in Q3 2026.